MoneyWorks4Me

Strides Pharma Science informs about press release

04 Nov 2019 Evaluate

Strides Pharma Science has informed about Press Release issued by the Company titled: USFDA announces Laboratory testing and analysis of Ranitidine and issues statement with acceptable NDMA limits. Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits. 

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1760.00
Dr. Reddys Labs. 1231.85
Cipla 1325.00
Lupin 1955.80
Zydus Lifesciences 1124.30
View more..